Oxidative stress and Parkinson's disease

Annals of the New York Academy of Sciences

Volumn 786, Issue , 1996, Pages 217-223

  Owen, A D ^a   Schapira, A H V ^b   Jenner, P ^a   Marsden, C D ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUTHIONINE SULFOXIMINE; FREE RADICAL; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; IRON; OXIDOPAMINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

BASAL GANGLION; CELL DEATH; CONFERENCE PAPER; ENZYME ACTIVITY; GLIA; HUMAN; LEWY BODY; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 0029741621     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb39064.x     Document Type: Conference Paper

References (25)

1. CLEETER, M. W. J., J. M. COOPER & A. H. V. SCHAPIRA. 1992. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenyl-pyridiniunv. evidence for free radical involvement. J. Neurochem. 58: 786-789.
2. ROSSETTI, Z. L., A. SOTGIU, D. E. SHARP, M. HADJICONSTANTINOU & N. H. NEFF. 1988. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro. Biochem. Pharmacol. 37: 4573-4574.
3. ADAMS, J. D. & I. N. ODUNZE. 1991. Biochemical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Biochem. Pharmacol. 41: 1099-1105.
4. +. Free Radical Biol. Med. 13: 581-583.
5. SCATTON, B., J. C. MONFORT, F. JAVOY-AGID & Y. ACID. 1984. Neurochemistry of monoaminergic neurones in Parkinson's disease. In Catacholamines: Neuropharmacology and Central Nervous System Therapeutic Aspects. 43-52. Alan R. Liss, Inc. New York.
6. YOUDIM, M. B. H., D. BEN SCHACHAR & P. RIEDERER. 1989. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in increased iron and melanin induced neurodegeneration? Acta Neurol. Scand. 126: 47-54.
7. DEXTER, D. T., J. SIAN, P. JENNER & C. D. MARSDEN. 1993. Implications of alterations in trace element levels in Parkinson's disease and other neurological disorders affecting the basal ganglia. Adv. Neurol. 60: 273-281.
8. SIAN, J., D. T. DEXTER, A. J. LEES, S. DANIEL, Y. AGIO, F. JAVOY-AGID, P. JENNER & C. D. MARSDEN. 1994. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting the basal ganglia. Ann. Neurol. 36: 348-355.
9. SCHAPIRA, A. H. V. 1994. Evidence for mitochondrial dysfunction in Parkinson's disease - a critical appraisal. Mov. Disord. 9: 125-138.
10. SCHAPIRA, A. H. V., V. M. MANN, J. M. COOPER, D. T. DEXTER, S. E. DANIEL, P. JENNER, J. B. CLARK & C. D. MARSDEN. 1990. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. 55: 2142-2145.
11. LESTIENNE, P., J. NELSON, P. RIEDERER, K. JELLINGER & H. REICH-MANN. 1990. Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect. J. Neurochem. 55: 1800-1812.
12. MIZUNO, Y., S. MATUDA, H. YOSHINA, H. MORI & N. HATTORI. 1994. An immunohistochemical study on α-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann. Neurol. 35: 204-210.
13. DEXTER, D. T., C. J. CARTER, F. R. WELLS, F. JAVOY-AGID, Y. AGID, A. LEES, P. JENNER & C. D. MARSDEN. 1989. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52: 381-389.
14. DEXTER, D. T., A. E. HOLLEY, W. D. FLITTER, T. F. SLATTER, F. R. WELLS, S. E. DANIEL, A. J. LEES, P. JENNER & C. D. MARSDEN. 1994. Increased levels of lipid hydropeoxides in parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 9: 92-97.
15. JENNER, P. 1994. Oxidative damage in neurodegenerative disease. Lancet 344: 796-798.
16. DEXTER, D. T., J. SIAN, S. ROSE, J. G. HINDMARSH, V. M. MANN, J. M. COOPER, F. R. WELLS, S. E. DANIEL, A. J. LEES, A. H. V. SCHAPIRA, P. JENNER & C. D. MARSDEN. 1994. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 35: 38-44.
17. SIAN, J., D. T. DEXTER, A. J. LEES, S. DANIEL, P. JENNER & C. D. MARSDEN. 1994. Glutathione-related enzymes in brain in Parkinson's disease. Ann. Neurol. 36: 356-361.
18. MITHOFFER, K., M. S. SANDY, M. T. SMITH & D. DI MONTE. 1992. Mitochondrial poisons cause depletion of reduced glutathione in isolated hepatocytes. Arch. Biochem. Biophys. 295: 132-136.
19. DI MONTE, D., M. S. SANDY & M. T. SMITH. 1987. Increased efflux rather than oxidation is the mechanism of glutathione depletion by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biophys. Res. Commun. 148: 153-160.
20. SAGARA, J., K. MIURA & S. BANNAI. 1993. Maintenance of neuronal glutathione by glial cells. J. Neurochem. 61: 1672-1676.
21. DAMIER, P., E. C. HIRSCH, P. ZHANG, Y. AGID & F. JAVOY-AGID. 1993. Glutathione peroxidase, glial cells and Parkinson's disease. Neurosci. Lett. 58: 343-346.
22. SILVKA, A., C. MYTILINEOU & G. COHEN. 1987. Histochemical evaluation of glutathione in brain. Brain Res. 409: 275-284.
23. ABRAMOVITZ, M., H. HOMMA, S. ISHIGALEI, F. TANSEY, W. CAMMER & I. LISTOWSKY. 1988. Characterization and localization of glutathione-S-transferase in rat brain and binding of hormones, neurotransmitters and drugs. J. Neurochem. 50: 50-57.
24. PILEBLAD, E., T. MAGNUSSON & B. FORNSTEDT. 1989. Reduction of brain glutathione by L-buthionine sulfoxamine potentiates the dopamine-depleting action of 6-hydroxydopamine in rat striatum. J. Neurochem. 52: 978-980.
25. SEATON, T. A., P. JENNER & C. D. MARSDEN. 1995. Thioctic acid does not restore glutathione levels or protect against potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain. J. Neurochem. In press.